Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Ullmann
AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis
Generation of Nanoparticles by Spark Discharge
Journal of Nanoparticle Research
Materials Science
Nanoscience
Condensed Matter Physics
Molecular Physics,
Simulation
Atomic
Bioengineering
Modeling
Nanotechnology
Chemistry
Optics
Related publications
Long-Term Safety of Adalimumab in Adult Patients With Plaque Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis
Clinical Rheumatology
Medicine
Rheumatology
Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)
OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis
Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study
British Journal of Dermatology
Dermatology
Medicine
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
SKIN The Journal of Cutaneous Medicine
Comparing the Efficacy and Safety of IL-17 Inhibitorsfor Treatment of Moderate-To-Severe Psoriasis: A Randomized Double Blind Pilot Study With a Review of Literature
Postepy Dermatologii I Alergologii
Dermatology
Allergy
Immunology
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study
British Journal of Dermatology
Dermatology
Medicine
